Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VRDN
VIRIDIAN THERAPEUTICS, INC.
NASDAQ
$23.08
▼ DOWN 3.35% (-0.80)

KEY STATISTICS

Market Cap$2.61 B
52w High$34.29
52w Low$13.18
Dividend Yield—
Frequency—
P/E-6.85
Volume778.88K
Shares Out.113.29M

COMPANY

LEADERSHIP

Stephen F. Mahoney
CHIEF EXECUTIVE
Stephen F. Mahoney

COMPENSATION 2026

Salary$700,000
Stock Awards$1,058,098
Incentive Plan Pay$630,000
All Other Comp.$6,438
Total$6,776,249

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 18, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
252

PRICE TARGET

Target High$43.00
Target Low$26.00
Target Median$39.00
Target Consensus$36.14

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$4.03M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2020-11-13Reverse1:15
2016-11-07Reverse1:15

PRICE

$23.08 ▼ DOWN 3.35% (−$0.80)
OVERLAYS
$23.20$23.40$23.609:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM23.08

About Viridian Therapeutics, Inc.

https://www.viridiantherapeutics.com ↗

Viridian Therapeutics, Inc. is a biotech company developing IGF-1R-targeting treatments for serious diseases like thyroid eye disease, with several candidates in clinical trials.

INDUSTRY

Biotechnology

A PRODUCT VIRIDIAN THERAPEUTICS, INC. IS KNOWN FOR

Veligrotug
Veligrotug

Veligrotug, Viridian Therapeutics' lead IV antibody therapy for Thyroid Eye Disease, is under FDA Priority Review with a decision expected by June 30, 2026, and aims to be the company's first commercial product.

COMPETITORS

COMPETITOR
AMGN COMPARE
IMVT COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License$70M $0 ▼$6K ▲$233K ▲
Collaboration$570K $279K ▼$135K ▼$51K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
136
LISTED HERE
24
RANKED BY POSITION SIZE
XBI
0.84% · 4.2M
VTI
0.00% · 3.4M
XSU.TO
0.07% · 2.3M
SCHA
0.05% · 468.9K
DFAS
0.05% · 331.4K
XSXD.L
0.06% · 250.0K
TMSL
0.16% · 202.1K
LABU
0.57% · 151.6K
LFSC
2.51% · 137.8K
SBIO
1.30% · 136.2K
FYC
0.17% · 101.4K
PRFZ
0.04% · 52.9K
FFSM
0.07% · 49.1K
RSSL
0.07% · 43.1K
BBSC
0.09% · 27.0K
TILT
0.02% · 19.8K
BBC
0.87% · 19.2K
STXK
0.10% · 3.9K
URTY
0.03% · 3.7K
VETS
0.13% · 2.2K
AVSC
0.00% · 802
USFMDN.MX
0.00% · 403
KBFR
0.07% · 348
RESM
0.08% · 200

INSTITUTIONAL OWNERSHIP

SHARES OWNED
72.10%
HOLDERS
316
TOP 12 OF 316 · RANKED BY POSITION SIZE
Fmr LLC
16.6M sh · $305.03M
Blackrock, Inc.
8.6M sh · $157.09M
Bellevue Group AG
6.7M sh · $123.67M
Paradigm Biocapital Advisors LP
6.7M sh · $123.52M
Kynam Capital Management, LP
6.5M sh · $118.56M
State Street Corp
6.1M sh · $112.52M
Price T Rowe Associates Inc /Md/
5.7M sh · $105.6M
Vanguard Group Inc
5.6M sh · $174.65M
Deep Track Capital, LP
5.4M sh · $116.11M
Fairmount Funds Management LLC
5.1M sh · $93.52M
Blackrock Inc.
4.8M sh · $62.1M
Vr Adviser, LLC
3.9M sh · $75.95M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF LEGAL OFFICER
Tousignant Jennifer
Purchase · 10.0K shares
2026-08-19
★
OFFICER: CHIEF LEGAL OFFICER
Tousignant Jennifer
Sale · 10.0K shares
2026-08-19
★
OFFICER: CHIEF MEDICAL OFFICER
Tripuraneni Radhika
Purchase · 40.0K shares
2026-08-14
★
OFFICER: CHIEF MEDICAL OFFICER
Tripuraneni Radhika
Sale · 40.0K shares
2026-08-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 4
OVERWEIGHT 1
10 GRADES IN THE LAST 12 MONTHS
Truist Securities BUY RBC Capital OUTPERFORM Needham BUY Wedbush OUTPERFORM Wells Fargo OVERWEIGHT Evercore ISI Group OUTPERFORM Goldman Sachs BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
IBRX$8.05COMPARE
COGT$34.67COMPARE
EWTX$42.76COMPARE
RCUS$29.21COMPARE
QURE$48.72COMPARE
GPCR$47.37COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE